Tarsier Pharma Ltd. · AMEX:TARX
Tarsier Pharma — IPO Roadshow (May 2026)
27 slides from Tarsier Pharma's IPO roadshow presentation, May 18, 2026
Slide 1: Changing Lives By Saving Sight - Roadshow Presentation
Changing Lives By Saving Sight May 2026 ROADSHOW PRESENTATION Filed Pursuant to Rule 433 Issuer Free Writing Prospectus Dated May 18, 2026 (To Preliminary Prospectus dated May 18, 2026) Registration Statement No. 333-295210
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS FORWARD-LOOKING STATEMENTS 2 About this Presentation This presentation (this "Presentation") is provided for informational purposes only regarding Tarsier Pharma Ltd. (the "Company"). The information contained herein does not purport to be all-inclusive or complete and the
Slide 3: Forward-Looking Statements (Cont.)
FORWARD-LOOKING STATEMENTS (CONT.) FORWARD-LOOKING STATEMENTS (CONT.) 3 Industry and Market Data In this Presentation, the Company relies on and refers to certain information and statistics obtained from third-party sources which the Company believes to be reliable. Some data is also based on the go
Slide 4: Offering Summary
4 OFFERING SUMMARY OFFERING SUMMARY Issuer Tarsier Pharma Ltd. ("Tarsier" or the "Company") Proposed Listing NYSE: TARX Shares Offered 5,000,000 Ordinary Shares with 15% Over-allotment Option. Pro-forma after giving effect of the split. Expected Price Range $ 8.00 to $ 10.00 per Ordinary Share Expec
Slide 5: Investor Highlights
INVESTOR HIGHLIGHTS INVESTOR HIGHLIGHTS Late-stage TRS01 program to address a >$5B market opportunity With efficient commercialization strategy Dazdotuftide-novel therapeutic approach To address unmet need in non-infectious anterior uveitis with potential, if approved, to become the first-line treat
Slide 6: Lead Program, TRS01 Eye Drops: Addressing the Unmet Need in Anterior Uveitis
LEAD PROGRAM, TRS01 EYE DROPS: LEAD PROGRAM, TRS01 EYE DROPS: ADDRESSING THE UNMET NEED IN ANTERIOR UVEITIS 6 A chronic, recurrent autoimmune disease | The immune system attacks the inside of the eye, causing inflammation, pain, and blindness 2nd & 3rd line treatment (steroid-sparing): Generic immun
Slide 7: The Standard of Care Is a 70-Year-Old Treatment with Sight-Threatening Side Effects
THE STANDARD OF CARE IS A 70-YEAR-OLD TREATMENT WITH SIGHT-THREATENING SIDE EFFECTS THE STANDARD OF CARE IS A 70-YEAR-OLD TREATMENT WITH SIGHT-THREATENING SIDE EFFECTS New/Recurrent Inflammation Pressure Controls Inflammation 16 mmHg Danger Zone Vision-Threatening IOP Spikes Irreversible Glaucoma &
Slide 8: The Need: Safe Uveitis Treatment That Doesn't Compromise Vision
THE NEED: SAFE UVEITIS TREATMENT THAT DOESN'T COMPROMISE VISION THE NEED: SAFE UVEITIS TREATMENT THAT DOESN'T COMPROMISE VISION 8 U.S. Patients with NIAU NIAU + OHT1 or Glaucoma NIAU + Glaucoma ABBREVIATIONS: NIAU=Non-infectious anterior uveitis; OHT=Ocular Hypertension; UG=Uveitic Glaucoma SOURCES:
Slide 9: Burden of Uveitic Glaucoma: Physician Perspective
74% of Uveitis Experts surveyed stated that current topical therapies are inadequate for Uveitic Glaucoma Poor Response to Glaucoma Surgery in Patients with UG Compared to Glaucoma without Uveitis PHYSICAN PERSPECTIVE BURDEN OF UVEITIC GLAUCOMA PHYSICAN PERSPECTIVE BURDEN OF UVEITIC GLAUCOMA More li
Slide 10: Our Solution: dazdotuftide
10 dazdotuftide (NCE) Steroid-free | Inspired by nature | Hybrid peptide molecule OUR SOLUTION OUR SOLUTION
Slide 11: Dazdotuftide: Novel Mechanism of Action
DAZDOTUFTIDE: NOVEL MECHANISM OF ACTION DAZDOTUFTIDE: NOVEL MECHANISM OF ACTION 11 Dazdotuftide: Novel hybrid peptide molecule that modulates inflammatory macrophages (M1) to IL-10 secreting anti-inflammatory macrophages (M2) to promote immune tolerance. MECHANISM OF ACTION: Promoting immune toleran
Slide 12: TRS4Vision: Design & Efficacy Outcomes
TRS4VISION: DESIGN EFFICACY OUTCOMES TRS4VISION: DESIGN & EFFICACY OUTCOMES ACC=0 or 1 64% of TRS01-treated patients reached clinically meaningful improvement of ACC Grade=0 or 1 (i.e., ≤5 cells) on Day 28 9 Days (Median) Inflammation Control To ACC Grade 0 Or Trace, The Main Sign Of Uveitis Phase 3
Slide 13: IOP Results: In Light of New Safety Threshold
13 IOP RESULTS: IN LIGHT OF NEW SAFETY THRESHOLD IOP RESULTS: IN LIGHT OF NEW SAFETY THRESHOLD *TRS4Vision Results: p-value<0.05; Consistent with FAS (Full Analysis Set); Post hoc analysis Steroids >30% Did Not Meet New IOP Threshold The New Goal in Uveitis: IOP <16 mmHg 16 TRS01 <8% Did Not Meet Ne
Slide 14: Dazdotuftide Exhibited a Favorable IOP Profile
• Higher proportions of steroid-treated patients had an IOP increase from baseline at each of the thresholds evaluated (≥5 mmHg, ≥7 mmHg, ≥10 mmHg) • Steroid-treated patients - increased risk for glaucoma development or worsening of existing glaucoma TRS01: Stable IOP Average IOP per Visit STEROIDS:
Slide 15: TRS4Vision Phase 3 Results Summary
TRS4VISION PHASE 3 RESULTS SUMMARY TRS4VISION PHASE 3 RESULTS SUMMARY 15 Safe and Well Tolerated TRS01 was well-tolerated with no drug-related SAEs IOP Safety TRS01-treated patients experienced meaningfully fewer IOP spikes compared to steroid-treated patients (p-value<0.05, post hoc analysis) Infla
Slide 16: TRS4Vision Data Supported an FDA-Agreed Regulatory Path
TRS4VISION SAFETY AND EFFICACY DATA SUPPORTED AN FDA-AGREED REGULATORY PATH TRS4VISION SAFETY AND EFFICACY DATA SUPPORTED AN FDA-AGREED REGULATORY PATH Efficacy Safety Regulatory Path Clinical Strategy: Designed to Align with FDA-Agreed Endpoints SPA Agreement: FDA Acknowledges that IOP Safety Const
Slide 17: SPA-Backed Tarsier-04 Trial
SPA-BACKED TARSIER-04 TRIAL SPA-BACKED TARSIER-04 TRIAL 17 Tarsier-04 trial will be considered successful if the IOP primary endpoint meets statistical significance; FDA requirement for approval is that the TRS01 benefits outweigh the risks. Patient Population Active Control Treatment Duration New I
Slide 18: Addressable >$5B Market Opportunity for TRS01
ADDRESSABLE >$5B MARKET OPPORTUNITY FOR TRS01 ADDRESSABLE >$5B MARKET OPPORTUNITY FOR TRS01 TAM 615,000 All NIAU SAM 160,000 NIAU + Glaucoma 283,000 NIAU + Glaucoma or OHT Total Addressable Market (US) 615,000 US Patients with NIAU 283,000 US Patients with NIAU and Comorbid Glaucoma or OHT Serviceab
Slide 19: Phased Commercial Launch Targeting High-Need Patients First
PHASED COMMERCIAL LAUNCH TARGETING HIGH- PHASED COMMERCIAL LAUNCH TARGETING HIGH- NEED PATIENTS FIRST 615,000 UNMET NEED TRS01 POTENTIAL TARGET APPROACH STAGED COMMERCIALIZATION Highest Risk No treatment alternatives High Risk Fast progression to UG Safer standard of care Steroid-free alternative Fi
Slide 20: Dazdotuftide-Based Pipeline
DAZDOTUFTIDE-BASED PIPELINE: Designed to Redefine Blinding Eye Disease Treatment Through Immune Tolerance DAZDOTUFTIDE-BASED PIPELINE: Designed to Redefine Blinding Eye Disease Treatment Through Immune Tolerance 20 Pre-clinical studies show bioavailability, tolerability and sustained drug release in
Slide 21: IP Portfolio Protection Strategy
IP PORTFOLIO PROTECTION STRATEGY 1 Tarsier owns or has license to 7 issued U.S. patents and 6 pending U.S. patents • The TRS01 is strategically protected through multiple layers of protection ⎼ Dazdotuftide composition of matter patent issued in the US and in multiple foreign jurisdictions 1 ; paten
Slide 22: Decades of Ocular Drug Development and Market Building Experience
DECADES OF OCULAR DRUG DEVELOPMENT AND MARKET BUILDING EXPERIENCE DECADES OF OCULAR DRUG DEVELOPMENT AND MARKET BUILDING EXPERIENCE DAPHNE HAIM-LANGFORD, Ph.D. Chairperson & CEO 25+ years of executive experience; Former VP, CEO and venture capitalist (Xenia) and BOD member in biotech and medtech com
Slide 23: Board of Directors & Scientific Advisory Board
BOARD OF DIRECTORS SCIENTIFIC ADVISORY BOARD BOARD OF DIRECTORS & SCIENTIFIC ADVISORY BOARD Atul Raut, M.D., Ph.D. Tarsier BOD; Sun Pharma Susan Benton Tarsier BOD Daphne Haim-Langford, Ph.D. Tarsier CEO & Chairperson Sascha Bucher Tarsier BOD Richard Eiswirth Tarsier Director Nominee Jennifer Thorn
Slide 24: Roadmap and Milestones
24 Q3 2026 2027 2027 2027 Initiate TRS01 Phase 3 Tarsier-04 Trial Submit IND for TRS02 Intermediate, posterior, and panuveitis Initiate TRS02 Phase 1/2 Dose Escalation Trial TRS01 Top-Line Results Tarsier-04 Trial TRS01 Eye Drops TRS02 Intravitreal Injection ROADMAP AND MILESTONES ROADMAP AND MILEST
Slide 25: Capital Strategy
25 6 5 4 0.7 61% 15% 13% 10% 2% Use of Proceeds $ (millions) CAPITAL STRATEGY CAPITAL STRATEGY Advance the clinical development of TRS01 through the initiation and completion of Phase 3 clinical program Advance preparations towards our potential NDA submission for TRS01 Research and development in s
Slide 26: Investor Highlights
INVESTOR HIGHLIGHTS INVESTOR HIGHLIGHTS Late-stage TRS01 program to address a >$5B market opportunity With efficient commercialization strategy Novel therapeutic approach To address unmet need in NIAU with potential, if approved, to become the first-line treatment in Uveitic Glaucoma Binding FDA SPA
Slide 27: Contact Details
Contact Details Investor & Media Relations: CORE IR Jules Abraham IR@Tarsierpharma.com Media Inquiries: CORE IR Jules Abraham Media@Tarsierpharma.com